- Trial phase
- Phase 2-ready (trial not yet initiated; no frunexian trial found in available ClinicalTrials.gov data)
- Time to market
- Unknown, Phase 2 has not started; if a trial began today, any approval would still be multiple years away, and the company is actively seeking a partner to take the asset forward.
- Why 2/10
- No hard, dated catalyst exists for frunexian in the next ~12 months: it is 'Phase 2-ready' with no registered trial, no readout, and no PDUFA date in any available source, the only pipeline-wide event (a July 2026 partnering process) is undated and company-wide, not a frunexian binary.
Frunexian alone is not a tradeable binary, it has no scheduled catalyst, no trial data, and an undisclosed mechanism, so any near-term CVKD move is driven by the company-wide partnering process and financing events, not by this drug. Watch for an Item 1.01 8-K announcing a definitive deal or a new Phase 2 registration on ClinicalTrials.gov; treat the ~$14 mean price target (3 analysts, ~690% implied upside) skeptically, and expect dilution risk given the ~33%-dilutive July placement, effective S-3 shelf, and insider selling.
Price Chart
Executive Summary
Frunexian is Cadrenal Therapeutics' (Nasdaq: CVKD) 'Phase 2-ready' pre-operative safety candidate, the least-advanced of three pipeline assets (alongside CAD-1005, Phase 3-ready for heparin-induced thrombocytopenia, and tecarfarin, Phase 3-ready in orphan indications) at a ~$6M market-cap company with no revenue and no approved products. On July 21, 2026, Cadrenal announced a strategic realignment into a Cardiac Acute Critical Care Franchise and a formal partnering process to out-license or co-develop frunexian and its other late-stage assets, but disclosed no binding agreements or financial terms.
How It Works
Cadrenal positions frunexian as a drug to protect patients around the time of cardiac surgery (its 'Pre-Operative Safety' pillar) within a franchise aimed at life-threatening blood-clotting and immune conditions. The specific mechanism is not described in any source available this session, the '-exian' name suffix hints at an anticoagulant class, but that is not confirmed in the data.
Trial Status
Per Cadrenal's July 21, 2026 8-K, frunexian is one of three late-stage assets in the company's 'Cardiac Acute Critical Care Franchise,' positioned in the 'Pre-Operative Safety' pillar and described as 'Phase 2-ready.' No frunexian-specific clinical trial record, FDA action, or catalyst exists in the local ClinicalTrials.gov/FDA datasets, and the company has initiated a formal process to out-license, monetize, or co-develop it along with CAD-1005 and tecarfarin.
The Two-Sided Case
Upcoming Catalysts
- Any definitive partnering / out-licensing agreement for frunexian or the franchise (would come via a material agreement 8-K, undated)
- Initiation of a Phase 2 trial for frunexian (undated; not yet registered in available ClinicalTrials.gov data)
- Potential capital raise or shelf takedown under the effective S-3 registration (dilution event)
- Quarterly financial results and any pipeline updates from Cadrenal
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Cadrenal Therapeutics, Inc. 8-K CVKD ·Originating report